First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors (vol 14, 1376551, 2024)

被引：0

作者：

Shimizu, Toshio ^{[1
,2
]}

Powderly, John ^{[3
]}

Abdul Razak, Albiruni ^{[4
]}

Lorusso, Patricia ^{[5
]}

Miller, Kathy D. ^{[6
]}

Kao, Steven ^{[7
]}

Kongpachith, Sarah ^{[8
]}

Tribouley, Catherine ^{[8
]}

Graham, Michelle ^{[8
]}

Stoll, Brian ^{[8
]}

Patel, Maulik ^{[8
]}

Sahtout, Mohammad ^{[8
]}

Blaney, Martha ^{[8
]}

Leibman, Rachel ^{[8
]}

Golan, Talia ^{[9
,10
]}

Tolcher, Anthony ^{[11
]}

机构：

[1] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[2] Kansai Med Univ Hosp, Int Canc New Drug Dev Ctr, Dept New Expt Therapeut, Osaka, Japan

[3] Carolina BioOncol Inst, Huntersville, NC USA

[4] Princess Margaret Canc Ctr, Canc Clin Res Unit CCRU, Toronto, ON, Canada

[5] Yale Univ, Yale Canc Ctr, New Haven, CT USA

[6] Indiana Univ, Melvin & Bren Simon Comprehens Canc Ctr, Dept Med, Indianapolis, IN USA

[7] Chris OBrien Lifehouse, Dept Med Oncol, Sydney, NSW, Australia

[8] AbbVie Bay Area, South San Francisco, CA USA

[9] Sheba Med Ctr, Inst Oncol, Ramat Gan, Israel

[10] Tel Aviv Univ, Oncol Inst, Sheba Med Ctr Tel Hashomer, Tel Aviv, Israel

[11] New Expt Therapeut NEXT Oncol, San Antonio, TX USA

来源：

FRONTIERS IN ONCOLOGY | 2025年 / 14卷

关键词：

advanced solid tumors; TGF-ss; 1; GARP; immunotherapy; anti-PD-1; antibody; combination drug therapy; investigational therapies; tumor microenvironment (TME);

D O I：

10.3389/fonc.2024.1544394

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页数：2